Friday, July 10, 2026

pharma · Tuberculosis · Meningococcal Meningitis

CanSino Biologics

CanSino Biologics clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Tianjin, CN HQ
2009 Founded
138 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Tianjin, CN
Founded
2009
Employees
138
Programs
3
Drugs
9
Patents
0
Intelligence · Clinical Programs

CanSino Biologics projects

1 ClinicalTrials.gov programs sponsored by CanSino Biologics.

CanSino Biologics has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)

    CanSino Biologics

    Meningococcal Meningitis

    phase 3 mab active

    1 trial

Frequently asked questions

How many clinical projects does CanSino Biologics have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.